Analysts Are Bullish on These Healthcare Stocks: NBIX, PSTI

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Neurocrine (NASDAQ: NBIX) and Pluristem (NASDAQ: PSTI) with bullish sentiments.

Neurocrine (NASDAQ: NBIX)

H.C. Wainwright analyst Andrew Fein reiterated a Buy rating on Neurocrine (NASDAQ: NBIX) today and set a price target of $139. The company’s shares closed yesterday at $81.08.

According to TipRanks.com, Fein is a 4-star analyst with an average return of 4.7% and a 47.2% success rate. Fein covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Strongbridge Biopharma Plc, and Cyclacel Pharmaceuticals.

Currently, the analyst consensus on Neurocrine is Strong Buy and the average price target is $105.40, representing a 30.0% upside.

In a report issued on April 23, Jefferies also maintained a Buy rating on the stock with a $105 price target.

See today’s analyst top recommended stocks >>

Pluristem (NASDAQ: PSTI)

In a report released today, Swayampakula Ramakanth from H.C. Wainwright maintained a Buy rating on Pluristem (NASDAQ: PSTI), with a price target of $3.50. The company’s shares closed yesterday at $1.32.

Ramakanth observed:

“Olga Smolentseva, Ph.D. – (646-975-6966) / osmolentseva@hcwresearch.com Clinical Program Forges Ahead With Two IND Approvals; Reiterate Buy PLX-PAD muscle injury Phase 3 cleared to begin. On April 25, Pluristem announced that the FDA has approved the plans for a Phase 3 study of the company’s cell therapy product, PLX-PAD, for the treatment of muscle injury following hip fracture surgery. The company is also working with the EMA to approve the protocol to conduct this study in Europe as well, and expects to initiate the study in both the US and Europe this year. In the previous 20-patient Phase 1/2 study, patients undergoing hip replacement surgery who were treated with the 150 million- cells dose (the “low dose” group) of PLX-PAD managed to achieve a 300% increase in muscle volume and a 500% increase in muscle strength after 26 weeks when compared to control patients.”

According to TipRanks.com, Ramakanth is a 3-star analyst with an average return of 2.3% and a 34.8% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Diffusion Pharmaceuticals Inc, IntelGenx Technologies, and Eleven Biotherapeutics.

Currently, the analyst consensus on Pluristem is Moderate Buy and the average price target is $3.25, representing a 146.2% upside.

In a report released yesterday, Maxim Group also maintained a Buy rating on the stock with a $3 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.